Navigation Links
Radiation after surgery doubles survival time for some lung cancer patients

Patients with lung cancer that has spread to mediastinal lymph nodes ?located between the chest, breastbone and spine ?who receive radiation after surgery and chemotherapy live twice as long as patients who do not receive radiation after surgery, according to a study presented at the plenary session November 6, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia.

The study was part of a larger randomized study, ANITA 1, which examined the effectiveness of chemotherapy after surgery in 840 non-small cell lung cancer patients and found that additional chemotherapy after surgery improves overall survival in cancer that has spread to the lymph nodes. In this study, radiation was not randomized nor mandatory but only recommended for patients whose disease had spread to the lymph nodes. 232 lung cancer patients received radiation after undergoing surgery to remove their tumor with or without chemotherapy.

Researchers found that additional radiation after chemotherapy benefited patients whose cancer had spread to mediastinal lymph nodes. At that stage, those who underwent chemotherapy and radiation after surgery lived almost two years longer (47 versus 24 months) than those patients who had only chemotherapy after surgery. "This is the first time that a clinical trial has examined the effectiveness of radiation after surgery for lung cancer," said Jean-Yves Douillard, M.D., Ph.D., lead author of the study and a medical oncologist at the Centre Rene Gauducheau in St Herblain, France. "The results show that radiation treatment should be considered for resected non-small cell lung cancer with involved mediastinal lymph nodes in addition to chemotherapy. The data observed in this study, however, needs to be confirmed in a prospective randomized trial of radiation, in addition to chemotherapy."
'"/>

Source:American Society for Therapeutic Radiology and Oncology


Page: 1

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Duke Experiments Boost Radiations Cancer-Killing Effects
3. Radiation-killed bacteria vaccine induces broad immune response in mice
4. Radiation-armed robot rapidly destroys human lung tumors
5. Radiation therapy combo cures prostate cancer long-term
6. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
7. Does vitamin C help prevent or treat the common cold? Maybe not, after all.
8. Stem cell treatment improves mobility after spinal cord injury
9. Bad aftertaste? New sensory on/off switch may cure bane of artificial sweetener search
10. New type of rejection blocker protects kidneys after transplant
11. Hurricane aftermath: Infectious disease threats from common, not exotic, diseases
Post Your Comments:
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... of ants, Shelley Berger, PhD, the Daniel S. Och ... Danny Reinberg, PhD, New York University, and Juergen Liebig, ... avenue of research for epigenetics -- the study of ... an organism,s characteristics, development, and even behavior. ...
... out what,s new (and important) in the Earth and space ... now for the best selection, News Media registration information, News ... new (and important) in the Earth and space sciences ... Moscone Convention Center, located at 747 Howard Street in San ...
... analysis, researchers at Emory University School of Medicine ... genetically more diverse than people of European descent, ... an isolated population. In addition, analyses of disease-related ... population indicate that only a minority of traits ...
Cached Biology News:Genome comparison of ants establishes new model species for molecular research 2Genome comparison of ants establishes new model species for molecular research 3Genome comparison of ants establishes new model species for molecular research 4AGU 2010 Fall Meeting: News media registration opens, book hotels now 2AGU 2010 Fall Meeting: News media registration opens, book hotels now 3AGU 2010 Fall Meeting: News media registration opens, book hotels now 4Analysis of Ashkenazi Jewish genomes reveals diversity, history 2Analysis of Ashkenazi Jewish genomes reveals diversity, history 3
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ... remaining soft. , This solid economic news is having a ...
(Date:12/24/2014)... 23, 2014 Pipette.com announces their ... followers can submit their #HolidayInTheLab pictures for a chance ... mates. , For those struggling to think of a ... Holiday in the Lab Contest provides the ideal holiday ... to send pictures of their chemistree, holiday sweaters, ...
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Amgen (NASDAQ: AMGN ) reported total revenue increased 3 ... $3,816 million in the third quarter of 2010.  Total product sales ... million versus $3,759 million in the third quarter of 2010.   ... third quarter of 2011, an increase of 3 percent compared to ...
... Oct. 24, 2011 Reaction Biology Corporation ("RBC"), ... services in epigenetics, today announced the rollout of ... research. RBC,s initial offerings will emphasize the histone ... has been no previous commercial source. ...
... Oct. 24, 2011 Synthetic Genomics Inc. (SGI), a ... to a variety of markets including biofuels, biochemicals, and ... a Mexico based investing and management company with extensive ... have announced the formation of a new company, Agradis. ...
Cached Biology Technology:Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 2Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 3Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 4Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 5Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 6Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 7Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 8Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 9Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 10Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 11Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 12Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 13Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 14Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 15Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 16Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 17Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 18Reaction Biology Launches Recombinant Methyltransferase Line 2Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies 2Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies 3Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies 4Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies 5
ANTI NO-TRYPTOPHAN CONJUGATE...
... Background/Kan Cloning Kit includes the ... for selection in E. coli. ... selection to eliminate high background. ... the reagents you need for ...
GOAT ANTI SLI...
Protein Phosphorylation...
Biology Products: